Validation of the Azeri version of the Pediatric Epilepsy Side Effects Questionnaire.
Childs Nerv Syst 2019;
35:2379-2383. [PMID:
31280354 DOI:
10.1007/s00381-019-04287-w]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/14/2019] [Accepted: 06/30/2019] [Indexed: 10/26/2022]
Abstract
PURPOSE
Long-lasting use of antiepileptic drugs in children with epilepsy negatively influences their quality of life and compliance. The purpose of this study was validation of the Azeri version of the Pediatric Epilepsy Side Effects Questionnaire (PESQ).
METHODS
We collected the PESQ from caregivers of children with epilepsy. In order to screen for comorbid behavioral and emotional problems, the Strengths and Difficulties Questionnaire (SDQ) was used. Demographic and medical data were collected through patient charts. We conducted factor analysis and assessed internal consistency and construct validity of the PESQ.
RESULTS
Caregivers of 120 patients with different epileptic syndromes completed the PESQ (age range 2-18; mean age 9.8 ± 4.0; male 56.7%; polytherapy 24%). The factor loading in the principal component analysis confirmed five-factor structure of the PESQ. The internal consistency coefficient of the total side effects scale of the PESQ was strong (0.86). Children receiving polytherapy showed higher scores on all subscales and the total score of the PESQ, supporting its construct validity. The total scores of the PESQ and the SDQ strongly correlated.
CONCLUSIONS
The PESQ can be used as a reliable and valid measure assessing antiepileptic drug side effects across the epilepsy spectrum.
Collapse